Amgen completes Abgenix acquisition
Biotech giant Amgen has completed the acquisition of Abgenix, a company specialising in the discovery, development and manufacture of human therapeutic antibodies. The acquisition provides Amgen with full ownership of panitumumab, which Abgenix co-developed with Amgen and which is being investigated for its ability to reduce tumour cell growth.
Biotech giant Amgen has completed the acquisition of Abgenix, a company specialising in the discovery, development and manufacture of human therapeutic antibodies. The acquisition provides Amgen with full ownership of panitumumab, which Abgenix co-developed with Amgen and which is being investigated for its ability to reduce tumour cell growth.
Kevin Sharer, Amgen's chairman and chief executive officer, said the move will help to ensure the company can deliver panitumumab "to every patient, every time, following FDA approval."
Abgenix was acquired for a total cash consideration of $2.2bn plus assumed debt. Amgen will pay stockholders of Abgenix $22.50 in cash per share of common stock held at the closing.